Emerging drugs for the treatment of alopecia areata

References

• Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;21(2):215–230.
   PubMed Web of Science ®Google Scholar
• Broadley D, McElwee KJ. A “hair-raising” history of alopecia areata. Exp Dermatol. 2020;29(3):208–222.
   PubMed Web of Science ®Google Scholar
• Senna M, Ko J, Tosti A, et al. Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims. Adv Ther. 2021;38(9):4646–4658.
   PubMed Web of Science ®Google Scholar
• Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123–130.
   PubMed Web of Science ®Google Scholar
• Iorizzo M, Tosti A. Emerging drugs for alopecia areata: JAK inhibitors. Expert Opin Emerg Drugs. 2018;23(1):77–81.
   PubMed Web of Science ®Google Scholar
• Rossi A, Muscianese M, Piraccini BM, et al. Italian guidelines in diagnosis and treatment of alopecia areata. G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2019;154(6):609–623.
   PubMed Web of Science ®Google Scholar
• Rebello D, Wang E, Yen E, et al. Hair growth in two alopecia patients after fecal microbiota transplant. ACG Case Rep J. 2017;4(1):e107.
   PubMedGoogle Scholar
• Rangu S, Lee JJ, Hu W, et al. Understanding the gut microbiota in pediatric patients with alopecia areata and their siblings: a pilot study. JID Innov Skin Sci Mol Popul Health. 2021;1(4):100051.
   PubMedGoogle Scholar
• Lu J, Zhang P, Hu R, et al. Gut microbiota characterization in Chinese patients with alopecia areata. J Dermatol Sci. 2021;102(2):109–115.
   PubMed Web of Science ®Google Scholar
• Delamere FM, Sladden MM, Dobbins HM, et al. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008 2;(2):CD004413. doi: 10.1002/14651858.CD004413.pub2.
   PubMed Web of Science ®Google Scholar
• Wagner AT. Industry perspective on alopecia areata. J Investig Dermatol Symp Proc. 2015;17(2):67–69.
   PubMedGoogle Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049.
   PubMed Web of Science ®Google Scholar
• Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, Ferdinand JR, et al. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol Baltim Md 1950. 2015;194(1):21–27.
   Google Scholar
• Gilhar A, Schrum AG, Etzioni A, et al. Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev. 2016;15(7):726–735.
   PubMed Web of Science ®Google Scholar
• Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15–24.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–2990.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves first systemic treatment for alopecia areata. 2022. [cited 2022 Jun 22]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata.
   Google Scholar
• Ryan GE, Harris JE, Richmond JM. resident memory T cells in autoimmune skin diseases. Front Immunol. 2021;12:652191.
   PubMed Web of Science ®Google Scholar
• Frohna PA, Ratnayake A, Doerr N, et al. Results from a first-in-human study of BNZ-1, a selective multicytokine inhibitor targeting members of the common gamma (γc) family of cytokines. J Clin Pharmacol. 2020;60(2):264–273.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. Phase 2 trial of BNZ-1 in patients with moderate to severe alopecia areata. 2021. [cited 2022 Jun 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT03532958
   Google Scholar
• Thorarensen A, Dowty ME, Banker ME, et al. Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans. J Med Chem. 2017;60(5):1971–1993.
   PubMed Web of Science ®Google Scholar
• Divito SJ, Kupper TS. Inhibiting Janus kinases to treat alopecia areata. Nat Med. 2014;20(9):989–990.
   PubMed Web of Science ®Google Scholar
• Dillon KAL. A comprehensive literature review of JAK inhibitors in treatment of alopecia areata. Clin Cosmet Investig Dermatol. 2021;14:691–714.
   PubMed Web of Science ®Google Scholar
• King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379–387.
   PubMed Web of Science ®Google Scholar
• Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. Study to evaluate the efficacy of tofacitinib in moderate to severe alopecia areata. Totalis And Universalis. 2019. [cited 2022 Jun 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT02299297.
   Google Scholar
• Jerjen R, Meah N, Trindade de Carvalho L, et al. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: a retrospective study. Pediatr Dermatol. 2021;38(1):103–108.
   PubMed Web of Science ®Google Scholar
• Ismail FF, Sinclair R. JAK inhibition in the treatment of alopecia areata - a promising new Dawn? Expert Rev Clin Pharmacol. 2020;13(1):43–51.
   PubMed Web of Science ®Google Scholar
• Jabbari A, Sansaricq F, Cerise J, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol. 2018;138(7):1539–1545.
   PubMed Web of Science ®Google Scholar
• Guo L, Feng S, Sun B, et al. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol JEADV. 2020;34(1):192–201.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29–32.
   PubMed Web of Science ®Google Scholar
• Liu LY, King BA. Tofacitinib for the treatment of severe alopecia areata in adults and adolescents. J Investig Dermatol Symp Proc. 2018;19(1):S18–S20.
   PubMedGoogle Scholar
• Kibbie J, Kines K, Norris D, et al. Oral tofacitinib for the treatment of alopecia areata in pediatric patients. Pediatr Dermatol. 2022;39(1):31–34.
   PubMed Web of Science ®Google Scholar
• King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847–853.
   PubMed Web of Science ®Google Scholar
• Messenger A, Harries M. Baricitinib in Alopecia Areata. N Engl J Med. 2022;386(18):1751–1752.
   PubMed Web of Science ®Google Scholar
• King B, Mesinkovska N, Mirmirani P, et al. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata. J Am Acad Dermatol. 2022;87(2):306–313.
   PubMed Web of Science ®Google Scholar
• Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80(2):566–568.
   PubMed Web of Science ®Google Scholar
• Ramírez-Marín HA, Tosti A. Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. Drug Des Devel Ther. 2022;16:363–374.
   PubMed Web of Science ®Google Scholar
• Robinson MF, Damjanov N, Stamenkovic B, et al. Efficacy and safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol Hoboken NJ. 2020;72(10):1621–1631.
   PubMed Web of Science ®Google Scholar
• Ramírez-Marín HA, Tosti A. Assessing the efficacy of selective JAK inhibitors for alopecia areata with a patient-centered approach. J Eur Acad Dermatol Venereol JEADV. 2022;36(4):494–495.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. PF-06651600 for the Treatment of alopecia areata (ALLEGRO-2b/3). 2022. [cited 2022 Jun 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT03732807.
   Google Scholar
• Eisman S, Sinclair R. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata. Expert Opin Investig Drugs. 2021;30(12):1169–1174.
   PubMed Web of Science ®Google Scholar
• Jo CE, Gooderham M, Beecker J. TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. Int J Dermatol. 2022;61(2):139–147.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. ATI-501 oral suspension compared to placebo in subjects with alopecia areata, alopecia universalis or alopecia totalis. 2020. [cited 2022 Jun 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT03594227
   Google Scholar
• Liu J, Lv B, Yin H, et al. Single ascending dose, multiple ascending dose and food effect study to evaluate the tolerance, pharmacokinetics of jaktinib, a new selective janus kinase inhibitor in healthy Chinese volunteers. Front Pharmacol. 2020;11:604314.
   PubMed Web of Science ®Google Scholar
• Cantelli M, Martora F, Patruno C, et al. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther. 2022;35(4):e15346.
   PubMed Web of Science ®Google Scholar
• Gambardella A, Licata G, Calabrese G, et al. Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata. Dermat Contact Atopic Occup Drug. 2021;32(1S):e85–e86.
   PubMed Web of Science ®Google Scholar
• Bennett M, Moussa A, Sinclair R. Successful treatment of chronic severe alopecia areata with abrocitinib. Australas J Dermatol. 2022;63(2):274–276.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kornacki D, Sun K, et al. Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2020;82(2):412–419.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. A study with jaktinib hydrochloride cream applied topically to subjects with alopecia areata (AA) .2022. [cited 2022 Jun 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT04445363.
   Google Scholar
• Mikhaylov D, Glickman JW, Del Duca E, et al. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2022. DOI:10.1007/s00403-022-02336-0.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. Efficacy of twice daily application of LEO 124249 ointment 30 mg/g for 12 weeks on eyebrow alopecia areata. 2018. [cited 2022 Jun 08] Available from: https://clinicaltrials.gov/ct2/show/NCT03325296.
   Google Scholar
• clinicaltrials.gov. A study of ATI-50002 topical solution for the treatment of alopecia areata. 2020. [cited 2022 Jun 08]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03354637
   Google Scholar
• HorizonTherapeutics. Daxdilimab (HZN-7734) Mechanism of action. Horizontherapeutics.com. 2021. [cited 2022 Jun 08]. Available from: https://www.horizontherapeutics.com/Media-Center/Video-Library/Daxdilimab-Mechanism-of-Action
   Google Scholar
• clinicaltrials.gov. Study of DAXDILIMAB for the treatment of moderate-to-severe alopecia areata. 2022. [cited 2022 Jun 07]. Available from: https://clinicaltrials.gov/ct2/show/NCT05368103.
   Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–824.
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Wang Q, Strauss L, et al. Revisiting the PD-1 pathway. Sci Adv. 2020;6(38):eabd2712.
   PubMed Web of Science ®Google Scholar
• AnaptysBio. ROSNILIMAB. 2022 [cited 2022 Jun 07]. Available from: https://www.anaptysbio.com/pipeline/rosnilimab/
   Google Scholar
• clinicaltrials.gov. A study to evaluate the efficacy and safety of rosnilimab (ANB030) in treatment of subjects with moderate-to-severe alopecia areata (AZURE). 2022.[cited 2022 Jun 07]. Available from: https://clinicaltrials.gov/ct2/show/NCT05205070.
   Google Scholar
• Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. Drugs. 2021;81(9):985–1002.
   PubMed Web of Science ®Google Scholar
• Mao-Draayer Y, Sarazin J, Fox D, et al. The sphingosine-1-phosphate receptor: a novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin Immunol Orlando Fla. 2017;175:10–15.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. Safety and efficacy of oral etrasimod in adult participants with moderate-to-severe alopecia areata. 2022. [cited 2022 Jul 06] Available from: https://clinicaltrials.gov/ct2/show/NCT04556734.
   Google Scholar